This study is looking at different ways to manage agitated delirium (a state of confusion and restlessness) in hospitalized cancer patients. Researchers are comparing the effects of haloperidol, chlorpromazine, valproate, and a placebo (an inactive substance) given through a vein. The goal is to see which of these, along with standard non-drug treatments, best reduces agitation and distress. You may be able to join if you are an adult with advanced cancer, are being seen by a palliative care team, and have hyperactive or mixed delirium. The main way success will be measured is by how often patients experience breakthrough restlessness over 72 hours. The study's current status is unclear.

Study design

This is a double-blind, randomized clinical trial planning to enroll 42 participants. This means neither you nor your doctors will know which treatment you are receiving.

What's involved

The study will measure your symptoms using the Edmonton Symptom Assessment Scale Questionnaire through study completion, an average of 1 year.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.